Advertisement
Advertisement
U.S. markets close in 5 hours 7 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Novozymes A/S (NZM2.BE)

Berlin - Berlin Delayed Price. Currency in EUR
47.24+0.39 (+0.83%)
As of 03:41PM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close46.85
Open47.15
Bid47.41 x 50000
Ask47.61 x 50000
Day's Range46.50 - 47.27
52 Week Range46.06 - 67.02
Volume9
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for NZM2.BE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Novozymes delivers historically strong full-year results

      Novozymes is delivering strong growth and earnings in a volatile market environment with 9% organic sales growth in 2022. This marks the highest organic sales growth in more than a decade, and Novozymes is confident about the 2023 outlook of 4-7%. COPENHAGEN, Denmark – January 26, 2026. In the 2022 financial year, Novozymes delivers 9% organic sales growth – 11% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 26.4%, and ROIC including goodwill before

    • Investing.com

      Novozymes shares slide after merger with rival Chr. Hansen unveiled

      By Scott Kanowsky

    • MarketWatch

      Novozymes and Chr. Hansen agree deal to merge

      The Danish companies will create a biological solutions provider with combined annual revenue of around 3.5 billion euros ($3.69 billion).

    Advertisement
    Advertisement